Italians first to use stem cells

@article{Abbott1992ItaliansFT,
  title={Italians first to use stem cells},
  author={Alison Abbott},
  journal={Nature},
  year={1992},
  volume={356},
  pages={465-465}
}
  • A. Abbott
  • Published 9 April 1992
  • Medicine
  • Nature
15 Citations

Терапия генетических заболеваний: актуальные направления разработки биомедицинских клеточных продуктов

Current trends in the development of biomedical cell products for the treatment of monogenic genetic diseases, such as severe combined immunodeficiency, recessive dystrophic epidermolysis bullosa, beta-haemoglobinopathies, alpha-1-antitrypsin deficiency, haemophilia A, and Duchenne muscular dystrophy are reviewed.

Treatment of Genetic Diseases: Current Trends in the Development of Biomedical Cell Products

Current trends in the development of biomedical cell products for the treatment of monogenic genetic diseases, such as severe combined immunodeficiency, recessive dystrophic epidermolysis bullosa, beta-haemoglobinopathies, alpha-1-antitrypsin deficiency, haemophilia A, and Duchenne muscular dystrophy are reviewed.

Advances in Chitin/Chitosan Characterization and Applications

The functionalization of polymeric substances is of great interest for the development of innovative materials for advanced applications. For many decades, the functionalization of chitosan has been

Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies

In the field of rare diseases, gene therapy is perhaps where the greatest potential lies and the use of fully characterized chitosan samples along with the utilization of complementary biophysical and biological techniques is key to bridging this gap of knowledge and identifying the optimal chitOSans for delivering a specific gene.

Обоснование методических подходов к экспертной оценке подлинности биомедицинских клеточных продуктов

Methodological approaches to identification testing of medicines containing living human cells (BCP analogues) currently used in international practice are summarized and methods used for BCP identification testing should ensure unambiguous authentication of the cell line according to its specification.

Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry

Cooperation between academia and industry is an opportunity to de-risk innovative approaches and ensure a faster and more economical development of therapies for diseases with high unmet medical needs and low-profit expectations.

Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks

Recent advances related to cancer genomics, proteomics, and systems biology are reviewed and suggest new perspectives in targeted therapy and precision medicine.

Gene Therapy in the Developing Countries

This review throws more light on gene therapy, its application and consequences in the developing countries.